These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Mechanisms of SARS-CoV-2 neutralization by shark variable new antigen receptors elucidated through X-ray crystallography. Ubah OC; Lake EW; Gunaratne GS; Gallant JP; Fernie M; Robertson AJ; Marchant JS; Bold TD; Langlois RA; Matchett WE; Thiede JM; Shi K; Yin L; Moeller NH; Banerjee S; Ferguson L; Kovaleva M; Porter AJ; Aihara H; LeBeau AM; Barelle CJ Nat Commun; 2021 Dec; 12(1):7325. PubMed ID: 34916516 [TBL] [Abstract][Full Text] [Related]
4. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Huo J; Le Bas A; Ruza RR; Duyvesteyn HME; Mikolajek H; Malinauskas T; Tan TK; Rijal P; Dumoux M; Ward PN; Ren J; Zhou D; Harrison PJ; Weckener M; Clare DK; Vogirala VK; Radecke J; Moynié L; Zhao Y; Gilbert-Jaramillo J; Knight ML; Tree JA; Buttigieg KR; Coombes N; Elmore MJ; Carroll MW; Carrique L; Shah PNM; James W; Townsend AR; Stuart DI; Owens RJ; Naismith JH Nat Struct Mol Biol; 2020 Sep; 27(9):846-854. PubMed ID: 32661423 [TBL] [Abstract][Full Text] [Related]
5. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein. Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385 [TBL] [Abstract][Full Text] [Related]
6. Development of Broad-Spectrum Nanobodies for the Therapy and Diagnosis of SARS-CoV-2 and Its Multiple Variants. He L; Wu Q; Zhang Z; Chen L; Yu K; Li L; Jia Q; Wang Y; Ni J; Wang C; Li Q; Zhai X; Zhao J; Liu Y; Fan R; Li YP Mol Pharm; 2024 Aug; 21(8):3866-3879. PubMed ID: 38920116 [TBL] [Abstract][Full Text] [Related]
7. Screening and Characterization of Shark-Derived VNARs against SARS-CoV-2 Spike RBD Protein. Chen YL; Lin JJ; Ma H; Zhong N; Xie XX; Yang Y; Zheng P; Zhang LJ; Jin T; Cao MJ Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142819 [TBL] [Abstract][Full Text] [Related]
8. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV. Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421 [TBL] [Abstract][Full Text] [Related]
9. Identification of nurse shark V Buffington J; Duan Z; Kwon HJ; Hong J; Li D; Feng M; Xie H; Ho M FASEB J; 2023 Jun; 37(6):e22973. PubMed ID: 37191949 [TBL] [Abstract][Full Text] [Related]
10. Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries. Yuan TZ; Garg P; Wang L; Willis JR; Kwan E; Hernandez AGL; Tuscano E; Sever EN; Keane E; Soto C; Mucker EM; Fouch ME; Davidson E; Doranz BJ; Kailasan S; Aman MJ; Li H; Hooper JW; Saphire EO; Crowe JE; Liu Q; Axelrod F; Sato AK MAbs; 2022; 14(1):2002236. PubMed ID: 34967699 [TBL] [Abstract][Full Text] [Related]
11. Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern. Valdovino-Navarro BJ; Dueñas S; Flores-Acosta GI; Gasperin-Bulbarela J; Bernaldez-Sarabia J; Cabanillas-Bernal O; Cervantes-Luevano KE; Licea-Navarro AF Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293124 [TBL] [Abstract][Full Text] [Related]
13. Binding Mechanism of Neutralizing Nanobodies Targeting SARS-CoV-2 Spike Glycoprotein. Golcuk M; Hacisuleyman A; Erman B; Yildiz A; Gur M J Chem Inf Model; 2021 Oct; 61(10):5152-5160. PubMed ID: 34581563 [TBL] [Abstract][Full Text] [Related]
14. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. Bertoglio F; Fühner V; Ruschig M; Heine PA; Abassi L; Klünemann T; Rand U; Meier D; Langreder N; Steinke S; Ballmann R; Schneider KT; Roth KDR; Kuhn P; Riese P; Schäckermann D; Korn J; Koch A; Chaudhry MZ; Eschke K; Kim Y; Zock-Emmenthal S; Becker M; Scholz M; Moreira GMSG; Wenzel EV; Russo G; Garritsen HSP; Casu S; Gerstner A; Roth G; Adler J; Trimpert J; Hermann A; Schirrmann T; Dübel S; Frenzel A; Van den Heuvel J; Čičin-Šain L; Schubert M; Hust M Cell Rep; 2021 Jul; 36(4):109433. PubMed ID: 34273271 [TBL] [Abstract][Full Text] [Related]
15. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD Elife; 2020 Oct; 9():. PubMed ID: 33112236 [TBL] [Abstract][Full Text] [Related]
16. Proteomics Platform Reveals Broad-Spectrum Nanobodies for SARS-CoV-2 Variant Neutralization. Zhang R; Huang L; Zhang X; Yu Y; Liang T; Wang H; Zhang X; Hu D; Wang B; Wang Y; Jiang J; Yu X J Proteome Res; 2024 May; 23(5):1559-1570. PubMed ID: 38603467 [TBL] [Abstract][Full Text] [Related]
17. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438 [TBL] [Abstract][Full Text] [Related]
18. Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library. Kim YJ; Lee MH; Lee SR; Chung HY; Kim K; Lee TG; Kim DY Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671877 [TBL] [Abstract][Full Text] [Related]
19. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern. Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR Front Immunol; 2021; 12():691715. PubMed ID: 34149735 [TBL] [Abstract][Full Text] [Related]
20. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants. Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]